LISINOPRIL AND NIFEDIPINE ADMINISTRATION INHIBITS THE EXVIVO UPTAKE OF [CA-45(2+] BY PLATELETS FROM HYPERTENSIVE DIABETIC-PATIENTS

1 The effect of administration of the angiotensin converting enzyme inhibitor (ACEI), lisinopril (Carace; 10-40 mg twice daily) and the calcium channel blocker, nifedipine (Adalat Retard; 20-40 mg twice daily) on ex vivo [Ca-45(2+)] uptake by platelets from hypertensive diabetic (type 1 and 2) patients was investigated. 2 At the end of at least 3 months treatment, blood was collected prior to the patient taking the morning dose of medication and washed platelets prepared. [Ca-45(2+)] uptake was monitored following the addition of adrenaline, isoprenaline and dibutyryl cAMP (dbcAMP), as well as in unstimulated (zero) platelets. 3 Both nifedipine and lisinopril significantly inhibited the ex vivo uptake of Ca-45(2+) by platelets when this process was stimulated by adrenaline, isoprenaline and dibutyryl cAMP. Basal uptake was also inhibited in both groups. 4 These data consolidate the hypothesis that ACE inhibitors may possess calcium channel/calcium mobilisation blocking properties. Apart from its hypertensive action, lisinopril may also reduce platelet activity via modulation of calcium dynamics, thereby reducing the incidence of vascular complications associated with diabetes mellitus.